Login / Signup

Impact of Canagliflozin on Kidney and Cardiovascular Outcomes by Type 2 Diabetes Duration: A Pooled Analysis of the CANVAS Program and CREDENCE Trials.

Sheldon W TobeThomas A MavrakanasHarpreet S BajajAdeera LevinNavdeep TangriApril SleeBrendon L NeuenVlado PerkovicKenneth W MahaffeyWally RapattoniFernando G Ang
Published in: Diabetes care (2024)
Our findings suggest that earlier treatment with canagliflozin confers consistent cardiorenal benefits to individuals with type 2 diabetes.
Keyphrases
  • type diabetes
  • quality improvement
  • cardiovascular disease
  • glycemic control
  • randomized controlled trial
  • insulin resistance
  • metabolic syndrome
  • combination therapy